Related Experiment Video
Updated: Jul 19, 2026
05:59
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Tardive syndromes in the elderly.
Kelvin L Chou1, Joseph H Friedman
1Department of Clinical Neurosciences, Brown Medical School, 227 Centerville Road, Warwick, RI 02886, USA. Kevin_Chou@brown.edu
Clinics in Geriatric Medicine
|September 27, 2006
Summary
Tardive syndromes, involuntary movements from dopamine-blocking drugs, are more common in older adults. This review covers their symptoms, causes, occurrence, and treatments in the elderly population.
Area of Science:
- Geriatric Medicine
- Neuropharmacology
- Movement Disorders
Background:
- Tardive syndromes involve involuntary movements resulting from long-term use of dopamine receptor-blocking medications.
- These neurological conditions disproportionately affect elderly individuals.
- The use of antipsychotic medications in the elderly population is rising.
Purpose of the Study:
- To provide a comprehensive overview of tardive syndromes specifically in elderly individuals.
- To summarize current knowledge on the clinical features, underlying mechanisms, prevalence, and therapeutic strategies for tardive syndromes in this demographic.
Main Methods:
- Literature review and synthesis of existing research on tardive syndromes.
- Focus on studies examining phenomenology, pathophysiology, epidemiology, and treatment in geriatric populations.
Main Results:
- Tardive syndromes present with a range of abnormal involuntary movements.
- Pathophysiology involves complex changes in the dopamine system.
- Epidemiological data indicate a higher incidence and prevalence in older adults.
Conclusions:
- Elderly patients represent a vulnerable group for developing tardive syndromes.
- Understanding the specific challenges in this population is crucial for effective management.
- Further research and clinical attention are needed to address tardive syndromes in the elderly.
More Related Videos
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...